Invesco Ltd. Relmada Therapeutics, Inc. Transaction History

Invesco Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $1.9 Million - $3.83 Million	103,578 Added 971.01%	114,245 $4.23 Million
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $25,492 - $46,875	1,545 Added 16.94%	10,667 $203,000
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $152,519 - $246,202	9,122 New	9,122 $247,000
Q1 2021 May 17, 2021	SELL	$31.52 - $39.28 $8.42 Million - $10.5 Million	-267,155 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$29.88 - $39.8 $65,437 - $87,162	2,190 Added 0.83%	267,155 $8.57 Million
Q3 2020 Nov 16, 2020	SELL	$34.42 - $43.78 $1.99 Million - $2.53 Million	-57,776 Reduced 17.9%	264,965 $9.97 Million
Q2 2020 Aug 14, 2020	BUY	$31.59 - $49.98 $1.79 Million - $2.83 Million	56,623 Added 21.28%	322,741 $14.4 Million
Q1 2020 May 15, 2020	SELL	$23.78 - $50.12 $74,169 - $156,324	-3,119 Reduced 1.16%	266,118 $9.08 Million
Q4 2019 Feb 14, 2020	BUY	$10.1 - $47.18 $2.72 Million - $12.7 Million	269,237 New	269,237 $10.5 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.